NS-050/NCNP-03 in Boys With DMD (Meteor50)
A Phase 1/2, First in Human, Multiple-dose, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-050/NCNP-03 in Boys With Duchenne Muscular Dystrophy (DMD)
Sponsor: NS Pharma, Inc.
This observational or N/A phase trial investigates Duchenne Muscular Dystrophy and is currently ongoing. NS Pharma, Inc. leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Apr 28, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: PHASE1/PHASE2 → None
-
Oct 2025 — Apr 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 2 earlier versions
-
Mar 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Oct 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.
Contact Information
- NS Pharma, Inc.
- Nippon Shinyaku Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .